## Question
Which molecular mechanism best explains the loss of function of CTLA4 p.Arg75Trp (UniProt P16410), and does one targeted computational test change the starting conclusion? [E1]

## Evidence
ClinVar lists the variant as pathogenic for CTLA4 haploinsufficiency-associated autoimmune lymphoproliferative syndrome, reviewed by an expert panel [E1]. It is very rare in gnomAD v4.1, observed once in about 1.46 million alleles [E2]. Residue 75 is highly conserved (ScoreCons 0.823) and EVE and popEVE predict it as deleterious [E8, E9, E10]. AlphaMissense scores the change as likely benign (0.2572) [E7]. UniProt places residues 68–77 in a beta strand [E6] and describes CTLA4 as a decoy receptor for CD80 and CD86 [E18]. IntAct records a CD80 interaction but does not map the interface to residues [E19]. In a large R75W family, affected and unaffected carriers did not differ in CTLA-4 expression or Treg percentage [E11]. No retrieved record reports ligand binding, trafficking or intrinsic function of R75W [G1].

## Agent-generated hypotheses
H1 (protein interaction, starting rank 1) proposes that R75W weakens CD80/CD86 capture while the protein is still expressed [H1]. H2 (stability, starting rank 2) proposes that R75W destabilises the Ig-V fold [H2]. Both are agent-generated hypotheses.

## Tests considered and the choice
Four tests were scored [T1, T2, T3, T4]. T1, a FoldX stability test, was chosen because it needs no compute time and is the only candidate that discriminates H2 [T1]. Structural context (T2) and ligand contact (T3) were rejected for low learning value. Structure comparison (T4) was rejected because it needs approval and 120 compute seconds [T4]. Safety cleared T1 without approval.

## Result
FoldX predicts ΔΔG −0.11 kcal/mol for R75W on the AlphaFold model, below the 2.0 kcal/mol destabilising threshold, with residue pLDDT 95.38 [T1, E20, E21]. This is a computational prediction, not an experimental measurement.

## Updated decision
H1 was favoured before the test and remains favoured after it. H2 is weakened [H1, H2]. The favourite did not change and no earlier result was refuted, so no reopening was recorded. H1 has no direct test yet.

## Uncertainty and validation still needed
FoldX error is near 1 kcal/mol, and T1 had no comparator substitutions at residue 75 [T1]. A neutral folding value does not show that binding is intact. H2's structural half, whether R75 has a buried polar partner in 9DQ3 or 1I85, is untested [H2, E14, E16]. No experimental structure carries R75W [G5]. Nothing here has been validated experimentally. The ClinVar classification [E1] and the low AlphaMissense score [E7] remain in tension.

## Next experiment
Proposed, not yet run: a computational binding test on the CTLA-4/B7-2 complex (1I85) [E16]. It would measure the distance from the R75 side chain to B7 atoms and the FoldX binding ΔΔG for R75W. H1 would be supported if R75 lies within about 5 Å of the partner and the binding ΔΔG is at least about 1 kcal/mol. H1 would be refuted if neither holds [H1].
